Loading…
← CockpitCompetitor Analysis › GDRX GoodRx Holdings, Inc. Class AOpen in the cockpit ↗

GoodRx Holdings, Inc. Class AGDRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Operator of a consumer platform providing prescription drug price comparisons, discount coupons and telehealth services.

Momentum strong 73
Mkt cap
$1.15B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$3.86M
20-day average traded
Fwd P/E
10.6×
forward earnings
ROIC−WACC
-2.5 pp
WACC 10.9%
Hurdle
-1 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$3.36
1D-3.2%
1W-8.0%
1M-4.5%
3M-5.6%
6M+33.3%
YTD+24.0%
1Y+17.9%
ATR %4.6%
Beta1.40
52w lowhigh13.6% off high

What GoodRx does

Operator of a consumer platform providing prescription drug price comparisons, discount coupons and telehealth services.

When a customer uses a coupon at the pharmacy, the pharmacy benefit manager that processes the claim pays GoodRx a fee, so its main income is per prescription filled, not what the consumer pays. Subscriptions and drug-maker advertising and savings programmes add smaller streams.

Products and services

  • Prescription discount/coupon platform
  • GoodRx Gold subscription
  • Telehealth/manufacturer solutions

Customers

  • Uninsured/underinsured consumers
  • Pharmacies
  • Pharmaceutical manufacturers (advertising/solution

Where it sits in the supply chain

  • Health care/consumer tech
  • Prescription drug savings platform
  • Drug price comparison, discount…

What could go right

  • Rising drug price/insurance-gap awareness
  • Pharma manufacturer advertising revenue growth

What could go wrong

  • PBM/insurer pricing competition
  • Regulatory scrutiny of drug pricing intermediaries

Moat: narrow (network effects, brand, data). Large consumer brand and pharmacy network create a two-sided marketplace effect, though PBMs can undercut pricing.

Headquarters: Santa Monica, California · Founded: 2011 · Employees: 697

Named competitors

GoodRx at a glance

Size GoodRx (GDRX) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.15B, the 2148th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.36 on 18 Nov 2026.

Performance Over six months the shares gained 33.3%, against +11.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 1.8% over the last twelve months (peer median +6.8%); the operating margin is 12.0% (peer median 6.2%).

Valuation It trades at 10.6× forward earnings against a peer median of 25.3× (3rd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.5 points below its cost of capital (10.9% WACC).

Short interest Short interest is 3.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026GDRX 131Peer median 111
Six months, rebased to 100: GoodRx against the median of its 20 peers (local-currency closes).

GoodRx financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$785M$797M$792M$750M$767M
Revenue growth—+1%+6%-2%—
Gross profit$625M$654M$675M$580M$648M
EBITDA$183M$192M$159M$163M$94.7M
Net income$16.2M$30.4M$16.4M-$8.87M-$32.8M
Free cash flow$197M$164M$183M$137M$143M
Capital expenditure$69.9M$74.0M$70.3M$55.8M$55.2M
Total debt$539M$543M$543M$711M$717M

Quarterly statements and history in the cockpit →

GoodRx competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%NUTXMETROPOLISOPKPNTGDIA688315AHCOCLARILMRI1833REG4694USPH4544TDOCAGLTHYROCAREWGSTTALOAMBEAGDRX6-month return →1-month return →
Up and to the right = strong over both horizons. GoodRx is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×NUTXMETROPOLISPNTGDIA688315CLARILMRI1833REG4694USPH4544AGLTHYROCAREWGSTTALOAMBEAGDRXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GoodRx is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%NUTXMETROPOLISPNTGDIA68831518334694GDRXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. GoodRx is the large dot.

GoodRx competitors and peer comparison

Head to head with its named competitors (GDRX vs AMZN vs UNH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
GoodRx GDRX$1.15B+33%-2%12%10.6×6.3%
Amazon AMZN$2.90T+1%+15%13%27.1×n/a
UnitedHealth UNH$314B-8%+3%5%15.4×3.1%

How GoodRx compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GoodRx against its 20 peers (data as of 18 Nov 2026)
MeasureGDRXPeer medianRank in peer set
1-month return-4.5%+2.2%7th lowest of 21
6-month return+33.3%+11.9%5th highest of 21
Distance from 52-week high-13.6%-24.0%7th highest of 21
Revenue growth (TTM)-1.8%+6.8%6th lowest of 21
Operating margin12.0%6.2%5th highest of 21
Forward P/E10.6×25.3×3rd cheapest of 18
Growth the price implies (Req g, 7 yrs)6.3%8.5%7th least demanding of 17
Growth delivered (Del g)+7.7%+10.7%6th lowest of 17
Hurdle (Req g minus delivered)-1.4 pp-0.4 pp8th least demanding of 17
ROIC minus cost of capital-2.5 pp-2.4 pp10th highest of 19
EV / EBITDA7.6×9.6×6th cheapest of 16
Net debt / EBITDA1.3×1.4×9th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%

Questions

Who are GoodRx's main competitors?
Named competitors: Amazon Pharmacy (AMZN), Optum Rx (UnitedHealth Group) (UNH). The cockpit's measured peer set (industry) also includes Nutex Health (NUTX), Metropolis Healthcare (METROPOLIS.NS), OPKO Health (OPK), Pennant (PNTG), Diagnostyka (DIA.WA), Novogene (688315.SS).
Is GoodRx expensive compared with its peers?
On forward p/e it trades at 10.6× against a peer median of 25.3×, 3rd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has GoodRx stock performed?
Over six months to 18 Nov 2026 the shares returned +33.3% against +11.9% for the median peer; over one year +17.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.